US-based food company Everytable has secured an investment of $25m to drive the growth of its food-as-medicine restaurants.

The funding was garnered as part of the initial closing of the firm's Series C-2 preferred stock financing round.

The funding round was led by the Dohmen Company Foundation (DCF) through the Dohmen Impact Investment Fund.

The round was also joined by the company's existing investors such as Creadev, Gullspång Re:foods and Kaiser Permanente Ventures.

It represents the first investment made by the Dohmen Impact Investment Fund since its launch in March 2023.

Everytable plans to use the fresh infusion to drive the growth of its retail stores and foodservice businesses across various places in the US, including Southern California, the Bay Area and New York City.

Last year, the firm tripled its retail presence to 50 locations. It also aims to open up to 25 new outlets by the year-end.

Everytable CEO and founder Sam Polk said: "We are inspired by the Dohmen Company's long history in the healthcare industry and their dedication to our shared mission to make nutritious food accessible to everyone, everywhere.

"The continued commitment from our investors, despite a steep decline in venture funding overall, speaks volumes about their confidence in our ability to address one of the most pressing and persistent issues of our time."

Participating at the 2022 White House Conference on Hunger Nutrition and Health, both DCF and Everytable committed to the US President's goal of ending hunger and minimising diet-related diseases by 2030.